Author: Jieun Choe
Narrative Builder
ファーマコビジランス
科学・医療関連コミュニケーション
Virtual Bodies for Real Drugs: AI May Speed Up Clinical Trials and Save More Lives
For years, drug companies had only one way to find out if a new medicine or vaccine works: patient-based clinical trials. But a community of virtual patients is promising to modernize the drug testing process by predicting drugs’ effects. The resulting studies, called in silico trials, use artificial intelligence (AI)-based simulation technology to mimic human … Continued
Clinical Researcher: モデリングとシミュレーションを使用した前競争的な研究は医薬品開発の近代化を促進する
It’s hard to imagine that 37 leading, global biopharmaceutical companies would be willing to partner to develop a new technology and progress a scientific field, but that is exactly what the members of the Simcyp Consortium have achieved. Working together in a pre-competitive, collaborative research environment, the consortium’s members are advancing physiologically based pharmacokinetic (PBPK) … Continued
Certara Announces Launch of Pediatrics Practice with Scientific and Regulatory Experts
Combination of experts and software helps accelerate pediatric drug development and increase clinical trial success rates PRINCETON, NJ – 2020年7月29日 – Today, Certara®, the global leader in biosimulation, launches Certara Pediatrics, a new practice area to help biopharmaceutical companies apply model-informed drug development to their pediatric programs and better navigate the changing regulatory landscape. … Continued
Everyone is hoping for silver bullet for COVID-19, but N.J.’s biopharma experts know collaboration could wind up key
Salvaging CNS Clinical Trials Halted Due to COVID‐19
The coronavirus disease 2019 (COVID‐19) pandemic has halted many ongoing central nervous system (CNS) clinical trials, especially in Alzheimer’s disease. These long‐duration trials involve many stakeholders, especially the patients and their family members, who have demonstrated their commitment to developing new therapeutic interventions for this devastating disease. We certainly do not want to lose all … Continued
Addressing the COVID-19 challenge with computer modeling & simulation
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development (MIDD)…
